BPL Medical Technologies takes over UK’s Penlon

BPL Medical Technologies (BPL Medical), a leading Indian medical devices company backed by global investment bank Goldman Sachs, on <g data-gr-id="34">Tuesday</g> announced the acquisition of UK-based Penlon Ltd (<g data-gr-id="19">Penlon</g>).

“We have acquired <g data-gr-id="20">Penlon</g>, a UK-based, leading global manufacturer of anaesthesia systems and <g data-gr-id="24">vaporizers</g> with worldwide distribution networks. “The acquisition will increase BPL Medical’s presence and distribution in other emerging and developed markets,” BPL Medical Technologies said.  <g data-gr-id="26">Penlon’s</g> product range complements BPL Medical’s existing portfolio and will help in expanding its presence in critical care segment. <g data-gr-id="27">Penlon</g> will continue to be based in and operated from the UK under the leadership of the existing management team, it added.

<g data-gr-id="28">Penlon</g> is an internationally recognised brand in critical care segment with a footprint in 96 countries, including India. With a strong focus on product innovation and a leading position in developed and emerging markets, the company designs, engineers and manufactures anaesthesia systems, <g data-gr-id="29">vaporizers</g> and other complementary products. These products are sourced by hospitals, pharmaceutical companies and anaesthesia system manufacturers worldwide. BPL Medical is one of the leading domestic medical device companies with over 300 personnel and a nationwide distributor network. In August 2013, Goldman Sachs invested in BPL Medical to fund the expansion of its medical devices business.

“This acquisition will help us penetrate the large critical care segment in India with <g data-gr-id="22">Penlon’s</g> world-renowned, technology-driven anaesthesia machines and <g data-gr-id="25">vaporizers</g>,” said Sunil Khurana, CEO, BPL Medical. It will also leverage <g data-gr-id="23">Penlon’s</g> R&D capabilities to develop many new products suitable for India and other emerging markets, Khurana added.